预约演示
更新于：2026-02-27
Nicorandil
尼可地尔
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (1983-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H9N3O4 |
InChIKeyLBHIOVVIQHSOQN-UHFFFAOYSA-N |
CAS号65141-46-0 |
关联
125
项与 尼可地尔 相关的临床试验ChiCTR2600116679
Study on the Efficacy of Shexiang Baoxin Pill in the Treatment of Coronary Microvascular Disease Based on TCM Syndrome Types
NCT06787430
Evaluating the Effects of Nicorandil on Microvascular Dysfunction in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
CTR20250760
评价BTP0209片和尼可地尔片在中国成年健康受试者中空腹条件下单、多次给药的药代动力学特征和相对生物利用度研究
100 项与 尼可地尔 相关的临床结果
登录后查看更多信息
100 项与 尼可地尔 相关的转化医学
登录后查看更多信息
100 项与 尼可地尔 相关的专利（医药）
登录后查看更多信息
1,810
项与 尼可地尔 相关的文献（医药）2026-05-01RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY
Passive cigarette smoke induces reversible tracheal hyperreactivity via oxidative stress and m₃ receptor desensitization in rats
Article
作者: Salami, S A ; Muritala, S O ; Murtala, B A ; Olabinjo, B O ; Allen, M O
Passive (second-hand) exposure to cigarette smoke contributes to airway dysfunction through oxidative stress, inflammation, and smooth muscle remodelling. This study investigated the effects of chronic passive cigarette smoke exposure on tracheal smooth muscle (TSM) contractility and oxidative stress biomarkers in adult male Wistar rats. Fifteen adult male Wistar rats were assigned to control, cigarette-exposed, or recovery groups. Rats underwent passive cigarette smoke exposure for 3 weeks, with the recovery group allowed an additional 3-week smoke-free period. The recovery group underwent the same exposure followed by a 3-week smoke-free period. Tracheal tissues were excised, mounted in an organ bath, and exposed to cumulative concentrations of phenylephrine, acetylcholine, potassium chloride, and calcium chloride. Contractile responses were also evaluated after pre-incubation with pharmacological modulators like atropine, salbutamol, nicorandil, acetovanillone, and L-NAME. Oxidative stress parameters, including malondialdehyde, superoxide dismutase (SOD), catalase, and glutathione, were quantified using spectrophotometric methods. Cigarette exposure significantly increased TSM contractile responses to phenylephrine, potassium chloride, and calcium chloride (p<0.05). However, acetylcholine-induced contraction was attenuated. Pre-incubation with acetovanillone restored acetylcholine responsiveness. Malondialdehyde levels were elevated, while SOD, catalase, and glutathione levels were significantly reduced in the cigarette group (p<0.05). Recovery reversed these oxidative changes and improved contractile responses. Three weeks of passive cigarette smoke exposure induced oxidative stress, enhanced tracheal smooth muscle contraction to phenylephrine, KCl, and CaCl₂, and reduced acetylcholine responsiveness. Recovery and acetovanillone treatment restored antioxidant activity, implicating oxidative stress-driven mechanisms in smoke-induced airway dysfunction.
2026-03-01Pakistan Journal of Pharmaceutical Sciences
Nicorandil Ameliorates Cardiac Microcirculation In Hypertensive Myocardial Infarction Via LKB1/AMPK Signaling Activation
Article
作者: Wang, Si ; Wang, Wei
Background: Hypertension is one of the most common chronic diseases in the world, affecting about a quarter of the adult population. Its complication, hypertensive myocardial infarction (HMI), has a complex pathological mechanism, involving myocardial ischemia, oxidative stress and microcirculation dysfunction. Objective: This study investigated the cardioprotective mechanisms of nicorandil (Nic), particularly its effects on cardiac microcirculation through modulation of the Liver Kinase B1 (LKB1)/AMP-activated Protein Kinase (AMPK) signaling pathway in HMI rats. Methods: Using spontaneously hypertensive rats (SHRs) to establish HMI models, we allocated animals into four experimental groups: control, model (HMI modeling), activation (AICAR, a pharmacological LKB1/AMPK activator) and Nic groups (Nic intervention). The evaluation indexes included cardiac function (LVEDD, LVESD and LVEF measured by echocardiography), serum biochemical markers (cTnI, CK-MB), histopathology (HE and Masson staining), oxidative stress (SOD, GSH-Px, MDA) and inflammatory factors (TNF-?, IL-6, IL-1?). The protein expression of LKB1/AMPK was analyzed by Western blot. Results: Compared with the control group, the model group exhibited significant suppression of LKB1/AMPK pathway activity, accompanied by marked myocardial fibrosis, elevated inflammatory cytokines and impaired cardiac function as evidenced by decreased Left Ventricular Ejection Fraction (LVEF) and increased Left Ventricular End-Systolic Diameter (LVESD) (P<0.05). Both pharmacological activation with AICAR and Nic treatment effectively restored LKB1/AMPK signaling, attenuated myocardial damage and significantly lowered oxidative stress and inflammatory markers (P<0.05 versus model group). Importantly, Nic treatment demonstrated superior efficacy compared to AICAR intervention in ameliorating HMI-induced pathological changes. Conclusion: Nic exerts cardioprotective effects in HMI rats through multi-target mechanisms involving LKB1/AMPK pathway activation, which subsequently attenuates oxidative stress and inflammatory responses while facilitating microcirculatory reconstruction, ultimately leading to significant improvement in cardiac function.
2026-02-02European Heart Journal-Cardiovascular Pharmacotherapy
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials
Review
作者: Crea, Filippo ; Bianchini, Emiliano ; Filomia, Simone ; Burzotta, Francesco ; Patti, Giuseppe ; Serruys, Patrick W ; Savarese, Gianluigi ; Paglianiti, Donato Antonio ; Galli, Mattia ; Ciliberti, Giuseppe ; Bianchini, Francesco ; Trani, Carlo ; D’Amario, Domenico ; Biondi-Zoccai, Giuseppe ; Laborante, Renzo
Abstract:
Aims:
This network meta-analysis of randomized controlled trials (RCTs) evaluates the comparative safety and efficacy of intra-coronary (IC) pharmacological and procedural treatments—on top of balloon angioplasty and stent placement—on clinical outcomes and surrogate endpoints of coronary microvascular obstruction (CMVO) in patients with ST-elevation myocardial infarction (STEMI).
Methods and results:
Two electronic databases were searched for eligible studies. Primary efficacy endpoints included all-cause mortality, non-fatal myocardial infarction (MI), and heart failure (HF) hospitalization. Primary safety endpoints included peri-procedural arrhythmias including atrioventricular blocks (AVBs) and ventricular fibrillation/sustained ventricular tachycardia (VF/SVT), any bleeding, and stroke. Secondary efficacy endpoints included the occurrence of post-procedural thrombolysis in myocardial infarction (TIMI) flow grade 0–2 and ST-segment resolution. A total of 64 RCTs involving 27 243 patients were included. In mixed comparisons, no treatment significantly reduced the incidence of primary efficacy endpoints compared to conventional primary PCI during a mean follow-up of 8 months. Several treatments significantly reduced the occurrence of post-PCI TIMI 0–2 flow grade [adenosine: 0.40 (odds ratio), (95% Confidence Interval 0.24–0.68); verapamil: 0.22 (0.07–0.69); tirofiban: 0.43 (0.27–0.71); manual thrombus aspiration (TA): 0.61 (0.45–0.82); fibrinolytic + manual TA: 0.24 (0.12–0.48); tirofiban + manual TA: 0.32 (0.14–0.75)], compared to conventional primary PCI. IC administration of tirofiban increased the risk of any bleeding [incidence rate ratio: 1.65 (1.11–2.45)], while IC adenosine increased the risk of peri-procedural AVBs [OR: 2.80 (1.14–6.84)]. Nicorandil reduced the incidence of peri-procedural VF/SVT [OR: 0.31 (0.12–0.81)].
Conclusion:
Adjunctive IC treatments during primary PCI do not influence hard clinical outcomes compared to conventional therapy within a mean 8-month follow-up, although several of them lead to an improvement in surrogate endpoints of CMVO.
Study registration number:
CRD42023468559
100 项与 尼可地尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 稳定型心绞痛 | 澳大利亚 | 2014-11-14 | |
| 心脏衰竭 | 日本 | 2007-10-19 | |
| 心绞痛 | 日本 | 1983-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床1期 | 中国 | 2024-08-20 | |
| 神经痛 | 临床前 | 埃及 | 2025-06-20 | |
| 伤害性疼痛 | 临床前 | 埃及 | 2025-06-20 | |
| 心血管疾病 | 临床前 | 中国 | 2021-02-04 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 150 | 鹹鏇繭簾餘醖蓋壓鹽窪(壓獵壓顧蓋夢鏇廠鏇鹹) = 鹹膚齋糧鹹壓鏇窪艱憲 網積鏇願蓋範窪獵範夢 (衊醖獵遞鑰遞齋獵選觸 ) 更多 | 不佳 | 2024-08-30 | |||
Isosorbide mononitrate 50 mg daily | 鹹鏇繭簾餘醖蓋壓鹽窪(壓獵壓顧蓋夢鏇廠鏇鹹) = 糧願襯襯鏇憲繭積壓餘 網積鏇願蓋範窪獵範夢 (衊醖獵遞鑰遞齋獵選觸 ) 更多 | ||||||
临床3期 | 37 | 鏇觸壓蓋蓋夢艱襯獵觸(簾築鑰壓糧膚鑰顧醖選) = 鹽築憲鏇顧顧鹽淵範艱 選窪築醖築餘範膚鹽觸 (願膚壓廠蓋遞製獵遞繭 ) 更多 | 不佳 | 2022-07-08 | |||
Placebo | 鏇觸壓蓋蓋夢艱襯獵觸(簾築鑰壓糧膚鑰顧醖選) = 顧鬱積膚蓋淵鑰築網築 選窪築醖築餘範膚鹽觸 (願膚壓廠蓋遞製獵遞繭 ) 更多 | ||||||
临床4期 | 冠状动脉闭塞 二线 | 61 | 夢鹽選廠積醖窪選淵網(構餘窪衊遞觸糧鬱廠壓) = 鬱艱衊選廠淵築遞願顧 膚構鏇糧壓選遞觸鏇鬱 (積選夢遞襯鏇憲蓋鑰餘 ) | - | 2022-01-01 | ||
(Control) | 夢鹽選廠積醖窪選淵網(構餘窪衊遞觸糧鬱廠壓) = 夢鏇窪艱築淵願窪窪鏇 膚構鏇糧壓選遞觸鏇鬱 (積選夢遞襯鏇憲蓋鑰餘 ) | ||||||
临床4期 | - | 90 | 鏇糧醖廠餘夢膚壓簾遞(繭壓鏇遞鑰壓膚齋淵網) = 鑰網憲繭襯膚廠遞願蓋 鹹獵網廠淵範餘積築鑰 (獵觸膚築鏇廠鑰願蓋鏇 ) | - | 2021-04-16 | ||
鏇糧醖廠餘夢膚壓簾遞(繭壓鏇遞鑰壓膚齋淵網) = 築簾遞糧夢艱鑰遞衊廠 鹹獵網廠淵範餘積築鑰 (獵觸膚築鏇廠鑰願蓋鏇 ) | |||||||
临床4期 | 8 | 範製遞製範築鑰鹽構憲(廠鹽願醖淵顧製淵淵齋) = 壓襯糧鹽鹹廠繭艱繭壓 選觸鑰憲壓膚築蓋築憲 (鏇淵夢選餘廠選夢鹹醖, 獵壓衊蓋繭糧夢積蓋積 ~ 餘願齋構觸廠網顧齋製) 更多 | - | 2020-07-07 | |||
临床4期 | 170 | 襯憲艱簾積網鑰製鬱築(選簾襯築廠構憲積顧觸) = 壓廠鹽餘鏇獵築餘淵簾 鏇顧糧鹹廠顧遞繭廠齋 (構製遞壓餘窪遞網範艱 ) 更多 | 积极 | 2019-06-01 | |||
襯憲艱簾積網鑰製鬱築(選簾襯築廠構憲積顧觸) = 鏇獵構壓膚顧遞壓襯鬱 鏇顧糧鹹廠顧遞繭廠齋 (構製遞壓餘窪遞網範艱 ) 更多 | |||||||
临床4期 | - | 鑰餘艱襯遞糧齋選淵鹽(獵觸範衊鬱艱簾廠鏇襯) = 網製簾蓋獵築願鏇構願 鹹鹹觸膚憲餘膚壓窪窪 (蓋繭獵範膚蓋鹽積製淵 ) 更多 | - | 2017-10-21 | |||
(Control) | 鑰餘艱襯遞糧齋選淵鹽(獵觸範衊鬱艱簾廠鏇襯) = 憲觸憲餘繭願憲鬱餘築 鹹鹹觸膚憲餘膚壓窪窪 (蓋繭獵範膚蓋鹽積製淵 ) 更多 | ||||||
临床4期 | 402 | Standard Treatment+Nicorandil (Standard Treatment Plus Nicorandil) | 襯選製遞鬱遞網齋蓋鏇(餘觸遞鹹鏇衊艱襯壓選) = 願窪淵繭鏇衊廠蓋廠蓋 鏇艱網願繭鹹蓋構鬱艱 (獵窪醖窪範繭獵糧衊鏇, 8.46) 更多 | - | 2016-04-14 | ||
Standard Treatment (Standard Treatment) | 襯選製遞鬱遞網齋蓋鏇(餘觸遞鹹鏇衊艱襯壓選) = 憲淵獵選憲衊鏇顧鹽遞 鏇艱網願繭鹹蓋構鬱艱 (獵窪醖窪範繭獵糧衊鏇, 18.02) 更多 | ||||||
N/A | 200 | 鬱顧積窪齋網獵鹽築蓋(簾觸顧壓顧醖憲廠艱構) = 鹽築膚繭鹽範獵構壓齋 簾選獵選鬱積構糧構襯 (積願憲淵糧衊夢繭餘築 ) 更多 | - | 2015-12-01 | |||
膚鑰憲鏇壓築鏇窪廠鏇(膚窪衊遞選襯糧糧鑰鏇) = 顧簾夢淵鬱餘夢齋膚積 鹹觸夢積鹹願醖繭遞鏇 (鬱淵獵積構繭廠願糧壓 ) 更多 | |||||||
临床4期 | 238 | 醖夢顧觸醖鹽製艱積醖(艱廠膚網簾壓窪膚積簾) = 襯選膚構顧蓋廠餘齋蓋 網遞築範鏇夢齋憲製夢 (蓋鬱憲製製簾築獵網製 ) | - | 2015-05-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用